James Purdy
Overview
Explore the profile of James Purdy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
455
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2024 Jun;
86(3):289-290.
PMID: 38897867
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...
2.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2023 May;
84(2):156-163.
PMID: 37179241
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...
3.
Hsu I, Rodgers J, Shinohara K, Purdy J, Michalski J, Roach 3rd M, et al.
Int J Radiat Oncol Biol Phys
. 2020 Nov;
110(3):700-707.
PMID: 33186617
Purpose: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by...
4.
Rosenthal S, Hu C, Sartor O, Gomella L, Amin M, Purdy J, et al.
J Clin Oncol
. 2019 Mar;
37(14):1159-1168.
PMID: 30860948
Purpose: Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could improve overall survival...
5.
Michalski J, Moughan J, Purdy J, Bosch W, Bruner D, Bahary J, et al.
JAMA Oncol
. 2018 Mar;
4(6):e180039.
PMID: 29543933
Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences....
6.
Galus M, Kirischian N, Higgins S, Purdy J, Chow J, Rangaranjan S, et al.
Aquat Toxicol
. 2013 Feb;
132-133:200-11.
PMID: 23375851
Pharmaceuticals are found in both receiving and drinking water due to their persistent release in waste-water effluents, raising concerns for environmental and human health. Chronic, aqueous exposure of zebrafish (Danio...
7.
Bekelman J, Deye J, Vikram B, Bentzen S, Bruner D, Curran Jr W, et al.
Int J Radiat Oncol Biol Phys
. 2012 Mar;
83(3):782-90.
PMID: 22425219
Purpose: In the context of national calls for reorganizing cancer clinical trials, the National Cancer Institute sponsored a 2-day workshop to examine challenges and opportunities for optimizing radiotherapy quality assurance...
8.
Bradley J, Bae K, Choi N, Forster K, Siegel B, Brunetti J, et al.
Int J Radiat Oncol Biol Phys
. 2010 Nov;
82(1):435-41.e1.
PMID: 21075551
Background: Radiation Therapy Oncology Group (RTOG) 0515 is a Phase II prospective trial designed to quantify the impact of positron emission tomography (PET)/computed tomography (CT) compared with CT alone on...
9.
Perks J, Turnbull H, Liu T, Purdy J, Valicenti R
Int J Radiat Oncol Biol Phys
. 2010 Jul;
79(3):915-9.
PMID: 20643510
Purpose: To analyze the daily setup variations in a cohort of intensity-modulated radiation therapy (IMRT) prostate cancer patients who had received daily image-guided RT without the use of fiducial markers...
10.
Fitzgerald T, Bishop-Jodoin M, Cicchetti M, Hanusik R, Kessel S, Laurie F, et al.
Int J Radiat Oncol Biol Phys
. 2010 Apr;
77(1):315-6.
PMID: 20394859
No abstract available.